Barclays’s CONMED CNMD Stock Holding History

Barclays’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,500	Closed	-$602K	–	5122
2023 Q4	$602K	Buy	+5,500	New	+$569K	﹤0.01%	3768

Other funds holding CNMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 34.64% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Barclays's CNMD Position: Q2 2026 in Review

Barclays reduced its CONMED (CNMD) stake by 76% in Q2 2026, selling an estimated $893K and leaving 7,912 shares worth $259K. The position accounts for ﹤0.01% of the portfolio, ranked #3566.

Barclays first reported a position in CNMD in Q2 2013 and has held it in 51 quarters since. The position peaked at $49.6M in Q2 2023. 246 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

Barclays held 7,912 shares of CONMED worth $259K as of Q2 2026.
Barclays sold 24,818 CONMED shares in Q2 2026, an estimated $893K.
CONMED made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3566 holding.
Barclays first reported a position in CONMED in Q2 2013 and has held it in 51 quarters since.
Barclays's CONMED position peaked at $49.6M in Q2 2023.
246 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.